Duty Stuart 4

What Happened
Duty Stuart, a director of Milestone Pharmaceuticals, received a derivative award (an option) for 77,000 shares on 2026-06-10. The grant is reported at $0.00 per share (no cash paid reported). This is an award/compensation grant rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-12 (timely filing).
• Transaction type: Grant/Award (derivative instrument) for 77,000 shares reported at $0.00.
• Shares owned after transaction: Not specified in the filing.
• Vesting: Option vests in twelve equal monthly installments beginning July 10, 2026; will be fully vested by the date of the next annual stockholders meeting, subject to continued service (see footnote).
• No sale or immediate cashless exercise reported—this is a standard equity compensation grant, not a disposition.

Context
This filing documents an equity compensation grant to a director. For retail investors, grants are routine corporate governance/compensation actions and do not, by themselves, indicate buying or selling sentiment. Because this is a derivative (option) with a time-based vesting schedule, there is no immediate change to company float or insider cash position until vesting/exercise/sale events occur.